FDA registered vs FDA approved: what documents prove

FDA registered vs FDA approved stem cell products are not the same thing, and the gap between them is where most diligence goes wrong. Registration under 21 CFR 1271.21 is a self-filed listing: an establishment submits it within 5 days of starting operations, or within 30 days of the rule’s effective date, and FDA does not review the product before the listing goes live. Approval, when a product needs it, means FDA granted a full biologics license under section 351 of the Public Health Service Act after reviewing a formal application. A product can be registered and never approved. Most HCT/P products stay on the lighter registration-only pathway based on how they are manufactured and used, not on paperwork.

A buyer, distributor, or investor doing diligence on a human cell or tissue based product is usually handed three documents: a certificate of analysis, donor eligibility records, and an FDA establishment registration number. Each proves something narrow and specific. None of them, alone or stacked together, proves the product is safe, effective, or cleared for a given use.

This article walks through what each document actually establishes under the regulation that governs it, how to verify each one independently, and what it means commercially when a company cannot produce clean versions of any of them.

Summary

• Registration and approval are separate legal events under different sections of federal law. A company can hold one without the other.
• A certificate of analysis reports one tested sample against a specification. It does not certify regulatory status or cover every unit in a shipment.
• Donor eligibility is a determination a named “responsible person” inside the establishment makes and documents, not an independent government check.
• FDA’s own establishment database can be searched directly, and its disclaimer states plainly that a registration hit is not a compliance or approval finding.
• Voluntary accreditations such as AABB and FACT sit on top of FDA’s baseline requirements. Their absence is not itself a violation.

Is “FDA registered” the same as “FDA approved” for a stem cell product?

No. Registration and approval sit on different legal tracks entirely.

21 CFR 1271.21 requires an establishment that manufactures an HCT/P, a human cell or tissue based product, to “register and submit a list of every HCT/P that your establishment manufactures within 5 days after beginning operations or within 30 days of the effective date”. That is a filing deadline, not a review. FDA does not evaluate the product before the listing goes live.

Whether a product also needs a full biologics license is a separate question, decided by the four-part test in 21 CFR 1271.10(a): minimal manipulation, homologous use only, no combination with another article, and no dependence on the metabolic activity of living cells for anything beyond autologous or closely limited allogeneic use. FDA’s guidance on the two hardest prongs of that test, minimal manipulation and homologous use, is where most classification disputes start. Fail any prong, and the product needs a section 351 biologics license, the approval track, before it can be marketed at all. FDA has also published a framework naming the specific guidance documents it uses to apply this test. A buyer can ask a company which of those documents it assessed its own product against, and expect a specific answer, not a general one.

A registration number by itself answers one question: whether the establishment filed a listing. It says nothing about which pathway the product is actually on.

What does a certificate of analysis for a biologic actually certify?

A certificate of analysis, a CoA, is a lab’s attestation that one tested sample from one batch met a defined specification. In the United States Pharmacopeia’s chapter on certificates of analysis, a CoA is described as “an important element of the overall supply chain controls needed to provide the user with assurance of excipient conformance to specification and its suitability for use in pharmaceuticals”. That definition is written for pharmaceutical excipients, but the same logic applies to biologics: a CoA is one control among several, not a government clearance.

What a CoA covers

A usable CoA states:

• The test name and the method used.
• The numeric result.
• The acceptance criteria the result was measured against.
• The batch or lot number the sample came from.

What it does not cover

A CoA does not state, and cannot state:

• Whether every other unit in the same shipment matches the tested sample.
• Whether the product is registered, let alone approved, under 21 CFR 1271.10.
• Whether the donor behind the material met FDA’s screening requirements.

A one-line CoA that reads only “passed all tests,” with no method, no numeric result, and no acceptance criteria listed, is a summary of a specification document, not the document itself. A buyer should ask for the underlying data.

What donor eligibility records are required, and what do they not tell you?

Donor eligibility is not a government determination. It is an internal one.

21 CFR 1271.50 states that “a responsible person, as defined in § 1271.3(t), must determine and document the eligibility of a cell or tissue donor”. The regulation defines an establishment and its obligations in 21 CFR 1271.3, but the eligibility determination itself happens inside the company, based on screening and testing it runs, not a review FDA conducts case by case.

Who makes the eligibility call

The “responsible person” is a specific, named individual inside the establishment, not a title borrowed for the paperwork. A buyer can ask who that person is by name, and request the eligibility determination record itself, not a summary letter describing it.

FDA’s own recommendations for how establishments should run donor screening and testing were still in draft form as of January 2025. That means the screening standard behind a given eligibility file may be more recent, or older, than the file itself, depending on when the determination was made. A buyer checking dates on a donor eligibility record should ask which version of FDA’s recommendations the establishment was following at the time.

How do you check whether an HCT/P establishment is actually registered?

FDA publishes a public tool for exactly this question: the Human Cell and Tissue Establishment Registration (HCTERS) Public Query Application. A buyer can search it directly by establishment name, function, product, state, or country, without asking the company for anything first.

A hit confirms the establishment filed a listing. It confirms nothing else. FDA’s own disclaimer on the tool states that “establishment registration and HCT/P listing does not constitute a determination that an establishment is in compliance with applicable rules and regulations, that the HCT/P is licensed or approved by FDA”. That sentence is worth reading twice. It is FDA, in its own words, saying its own registration database is not an approval list.

A miss is also informative. An establishment manufacturing an HCT/P that should be listed under 21 CFR 1271.21 but is not in HCTERS is outside the baseline requirement, regardless of what it claims elsewhere.

What do voluntary accreditations like AABB and FACT add beyond the FDA minimum?

AABB and FACT are the two major voluntary accreditors active in this space, and voluntary is the operative word. Neither is a regulatory requirement.

AABB’s cellular therapy standards set “requirements for the donor eligibility and collection, processing, storage, and administration of any type of cellular therapy product”. FACT publishes standards developed through committee and public review, built on the premise that “quality care requires proactive management of both clinical and laboratory practices”.

Both sit on top of FDA’s baseline, not instead of it. A company can be fully compliant with federal registration and donor eligibility requirements and hold neither accreditation. Its absence is a data point for a buyer to weigh, not a compliance failure to flag. Accreditation cost, timeline and renewal cadence are not asserted here; a buyer should request them directly from the accreditor rather than assume them from this article.

What happens when a company cannot produce these documents cleanly?

The enforcement pattern is instructive. An FDA warning letter issued in February 2026 illustrates the rule in action: an establishment cited over a paperwork and labeling deficiency, not a clinical outcome. The letter states the cited product was “a misbranded drug under section 502(f)(1) of the FD&C Act”. Misbranding is a labeling and documentation category. It is the enforcement lane a clean paper trail is built to avoid.

The commercial cost is direct. A company that cannot produce a specific certificate of analysis, name its responsible person for donor eligibility, or confirm its own HCTERS listing is not failing a technicality. It is failing the exact questions any serious buyer, distributor, or investor asks before moving forward.

What to do next

1. Search HCTERS by establishment name and confirm the registration is active, not just historical. Anyone can run this check directly.
2. Request the certificate of analysis for the specific lot, not a template, and confirm it lists test name, result, acceptance criteria, and method.
3. Ask who the establishment’s responsible person for donor eligibility determinations is, and request the eligibility determination record itself.
4. Ask the company to walk through each of the four 21 CFR 1271.10(a) criteria for its own product, and whether it is marketed as a registration-only HCT/P or requires a biologics license.
5. Check for AABB or FACT accreditation and treat either as supplementary information, not a substitute for the steps above.
6. Search FDA’s warning letter database for the establishment name before closing diligence.